Ann: First Patient dosed in ATH434 Phase 2 Clinical Trial, page-12

MSA is a rare disease, 5 cases in 100.000 and so in NZ with 5 million people, there are some 250 cases. When you want to find the cases in the very early phase, there may be less than 50 cases in New Zealand. To avoid this problem, there will be 30 different places to recruit the patients for this phase 2 study. The study needs only 60 patients. So this problem was solved already when the study plan was done. U.K. and Italy together with their over 100 million people have at least 5000 MSA patients and the USA alone has at least over 15.000, etc. Finding 60 very early cases for this study will not be a big problem.